21 / 2017-11-13 23:08:32
CLINICAL THERAPEUTIC EFFECTS OF HEPATIC ARTERIAL CHEMOEMBOLIZATION COMBINED WITH CETUXIMAB ON PATIENTS WITH COLORECTAL LIVER METASTASES
Parking Studies, Parking Demand, Urban Transportation System, On Street Parking
全文待审
li sihua / dfyk wqrt34t college
Objective: To discuss clinical therapeutic effects of hepatic arterial chemoembolization combined with cetuximab on patients with colorectal liver metastases. Methods: 50 patients with colorectal liver metastases admitted by our hospital from February 2010 to February 2012 were selected and divided into observation group and control group with 25 patients in each by random lottery. Hepatic arterial chemoembolization was given to patients in control group, and cetuximab was used based on it for patients in observation group. After treatment, clinical therapeutic effects, life quality and adverse effects of patients were compared between two groups. Three years of follow-up was conducted for patients in two groups, and survival rate was analyzed. Results: After treatment, the effective rate of observation group was 88%, significantly higher than 64% for control group. CEA (18.53±3.04) μg/L, CA242 (31.24±2.85) IU/ml and CA19-1 (34.68±3.06) KU/ml for patients in observation group were significantly lower than CEA (33.27±4.23) μg/L, CA242 (53.13±4.87) IU/ml and CA19-1 (62.35±6.73) KU/ml in control group, while the life quality and survival rate of observation group were significantly higher than those of control group with statistical significance (P<0.05). The incidence rate of adverse effects, including acneiform rash of patients in observation was 80%, significantly higher than 4% in control group with statistical significance (P<0.05), while the incurrence rate of adverse effects, including nausea and vomiting and diarrhea had no statistical significance (P>0.05). Conclusion: The therapeutic effects of hepatic arterial chemoembolization combined with cetuximab on patients with colorectal liver metastases were definite that it is worth to be promoted with effective improvement of life quality and survival rate.
重要日期
  • 会议日期

    12月13日

    2017

    12月20日

    2018

  • 10月10日 2018

    摘要截稿日期

  • 10月20日 2018

    摘要录用通知日期

  • 10月25日 2018

    初稿截稿日期

  • 11月08日 2018

    初稿录用通知日期

  • 11月28日 2018

    终稿截稿日期

  • 12月20日 2018

    注册截止日期

主办单位
DMIC
联系方式
移动端
在手机上打开
小程序
打开微信小程序
客服
扫码或点此咨询